---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-21-000064"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2021-12-23T23:59:59+00:00"
generated_at: "2026-06-27T22:46:55.689074+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Neurocrine Biosciences' license with Heptares effective; $100M upfront due

## Summary
- Collaboration and License Agreement with Heptares Therapeutics becomes effective Dec 22, 2021 after HSR clearance.
- Neurocrine to pay Heptares $100M upfront within ten days of effective date.
- Agreement originally entered Nov 22, 2021; HSR waiting period expired Dec 22, 2021.

## SEC filing metadata
- accession: 0000914475-21-000064
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2021-12-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447521000064/0000914475-21-000064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447521000064/nbix-20211222.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-21-000064
- JSON: https://secwatch.observer/filing/0000914475-21-000064.json
- Plain text: https://secwatch.observer/filing/0000914475-21-000064.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.